CTOR 8-K
Citius Oncology, Inc. (CTOR)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation)
| (Commission File Number) | (IRS Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s
telephone number, including area code (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
On December 27, 2024, we issued a press release announcing our results of operations for the full year of fiscal 2024. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.
The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |
| 99.1 | Press release, dated December 27, 2024. | |
| 104 | Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL). |
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CITIUS ONCOLOGY, INC. | |
| Date: December 27, 2024 | /s/ Leonard Mazur |
| Leonard Mazur | |
| Chairman and Chief Executive Officer |
2
Exhibit 99.1
Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update
CRANFORD, N.J., December 27, 2024 -- Citius Oncology, Inc. (“Citius Oncology” or the “Company”) (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal full year ended September 30, 2024.
Fiscal Full Year 2024 Business Highlights and Subsequent Developments
| - | Achieved U.S. Food and Drug Administration (FDA) approval of LYMPHIR™ (denileukin diftitox-cxdl), an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL); |
| - | Began trading on the Nasdaq exchange under the ticker symbol CTOR on August 13, 2024, following completion of the merger of Citius Pharma’s oncology subsidiary with TenX Keane to form Citius Oncology, Inc., a standalone publicly traded company; |
| - | Advanced manufacturing, marketing and sales activities in preparation for commercial launch of LYMPHIR in the first half of 2025; key activities included: |
| o | Manufactured initial inventory for launch and finalized supply chain agreements, |
| o | Initiated recruitment of targeted field force with contract sales organization, |
| o | Launched a marketing awareness campaign and engaged with all leading CTCL prescribers, |
| o | Applied for a unique J-code within the Healthcare Common Procedure Coding System (HCPCS) to facilitate accurate reimbursement, |
| o | Secured inclusion of LYMPHIR in the National Comprehensive Cancer Network (NCCN) guidelines, critical to clinical decision-making in oncology and hematology, influencing treatment practices and payor reimbursement in the U.S., and |
| o | Initiated development of the patient support center to help patients access LYMPHIR expeditiously; |
| - | Supported two investigator-initiated trials to explore LYMPHIR’s potential as an immuno-oncology combination therapy being conducted at the University of Pittsburgh Medical Center and the University of Minnesota; and, |
| - | Shared interim trial results with the clinical community at the Society for Immunotherapy of Cancer Conference (SITC) of University of Pittsburgh Medical Center’s Phase I trial of LYMPHIR with checkpoint inhibitor pembrolizumab. |
| o | The combination of these two immunomodulatory agents showed clinical benefit in relapsed or refractory gynecological neoplasms, resulting in: |
| § | 27% objective response rate and 33% clinical benefit rate with median progression free survival of 57 weeks (range: 30-96 weeks), and |
| § | A manageable safety profile whereby the regimen was well-tolerated with reversible treatment emergent adverse events and no definitive immune-related adverse events greater than or equal to grade 3 documented. |
Financial Highlights
| - | R&D expenses were $4.9 million for the full year ended September 30, 2024, compared to $4.2 million for the full year ended September 30, 2023; |
| - | G&A expenses were $8.1 million for the full year ended September 30, 2024, compared to $5.9 million for the full year ended September 30, 2023; |
| - | Stock-based compensation expense was $7.5 million for the full year ended September 30, 2024, compared to $2.0 million for the full year ended September 30, 2023; and, |
| - | Net loss was $21.1 million, or ($0.31) per share for the full year ended September 30, 2024 compared to a net loss of $12.7 million, or ($0.19) per share for the full year ended September 30, 2023. |
“Reflecting on 2024, Citius Oncology has achieved pivotal milestones that underscore our commitment to advancing cancer therapeutics,” stated Leonard Mazur, Chairman and CEO of Citius Oncology. “The FDA’s approval of LYMPHIR for the treatment of cutaneous T-cell lymphoma marks a significant advancement in providing new options for patients battling this challenging disease. It is the only targeted systemic therapy approved for CTCL patients since 2018 and the only therapy with a mechanism of action that targets the IL-2 receptor. Additionally, the successful merger forming Citius Oncology, now trading on Nasdaq under the ticker CTOR, strengthens our position in the oncology sector. We expect it to facilitate greater access to capital to fund LYMPHIR’s launch and the Company’s future growth. With a Phase I investigator-initiated clinical trial combining LYMPHIR with pembrolizumab demonstrating promising preliminary results, indicating potential for enhanced treatment efficacy in recurrent solid tumors, and preliminary results expected from a second investigator trial with CAR-T therapies in 2025, we remain excited about the potential of LYMPHIR as a combination immunotherapy.”
“These accomplishments reflect the dedication of our team and the trust of our investors. As we look ahead, we remain steadfast in our mission to develop innovative therapies that improve the lives of cancer patients worldwide,” added Mazur.
2
Full Year 2024 Financial Results:
Research and Development (R&D) Expenses
R&D expenses were $4.9 million for the full year ended September 30, 2024, compared to $4.2 million for the full year ended September 30, 2023. The increase reflects development activities completed for the resubmission of the Biologics License Application of LYMPHIR in January 2024, which were associated with the complete response letter remediation.
General and Administrative (G&A) Expenses
G&A expenses were $8.1 million for the full year ended September 30, 2024, compared to $5.9 million for the full year ended September 30, 2023. The increase was primarily due to costs associated with pre-commercial and commercial launch activities of LYMPHIR including market research, marketing, distribution and drug product reimbursement from health plans and payers.
Stock-based Compensation Expense
For the full year ended September 30, 2024, stock-based compensation expense was $7.5 million as compared to $2.0 million for the prior year. The primary reason for the $5.5 million increase was due to the amounts being realized over 12 months in the year ended September 30, 2024, as compared to three months post-plan adoption in the year ended September 30, 2023.
Net loss
Net loss was $21.1 million, or ($0.31) per share for the year ended September 30, 2024, compared to a net loss of $12.7 million, or ($0.19) per share for the year ended September 30, 2023. The $8.5 million increase in net loss was primarily due to the increase in our operating expenses.
About Citius Oncology, Inc.
Citius Oncology specialty is a biopharmaceutical company focused on developing and commercializing novel targeted oncology therapies. In August 2024, its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology’s competitive positioning. Citius Oncology is a publicly traded subsidiary of Citius Pharmaceuticals. For more information, please visit www.citiusonc.com
3
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as “will,” “anticipate,” “estimate,” “expect,” “plan,” “should,” and “may” and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Oncology are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; risks related to research using our assets but conducted by third parties; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission (“SEC”) filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC’s website at www.sec.gov, including in Citius Oncology’s Annual Report on Form 10-K for the year ended September 30, 2024, filed with the SEC on December 27, 2024, as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Investor Contact:
Ilanit Allen
908-967-6677 x113
Media Contact:
STiR-communications
Greg Salsburg
-- Financial Tables Follow –
4
CITIUS ONCOLOGY, INC.
CONSOLIDATED BALANCE SHEETS
SEPTEMBER 30, 2024 AND 2023
| 2024 | 2023 | |||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 112 | $ | — | ||||
| Inventory | 8,268,766 | — | ||||||
| Prepaid expenses | 2,700,000 | 7,734,895 | ||||||
| Total Current Assets | 10,968,878 | 7,734,895 | ||||||
| Other Assets: | ||||||||
| In-process research and development | 73,400,000 | 40,000,000 | ||||||
| Total Other Assets | 73,400,000 | 40,000,000 | ||||||
| Total Assets | $ | 84,368,878 | $ | 47,734,895 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable | $ | 3,711,622 | $ | 1,289,045 | ||||
| License payable | 28,400,000 | — | ||||||
| Accrued expenses | — | 259,071 | ||||||
| Due to related party | 588,806 | 19,499,119 | ||||||
| Total Current Liabilities | 32,700,429 | 21,047,235 | ||||||
| Deferred tax liability | 1,728,000 | 1,152,000 | ||||||
| Note payable to related party | 3,800,111 | — | ||||||
| Total Liabilities | 38,228,540 | 22,199,235 | ||||||
| Stockholders’ Equity: | ||||||||
| Preferred stock - $0.0001 par value; 10,000,000 shares authorized: no shares issued and outstanding | — | — | ||||||
| Common stock - $0.0001 par value; 100,000,000; 71,552,402 and 67,500,000 shares issued and outstanding at September 30, 2024 and 2023, respectively | 7,155 | 6,750 | ||||||
| Additional paid-in capital | 85,411,771 | 43,658,750 | ||||||
| Accumulated deficit | (39,278,587 | ) | (18,129,840 | ) | ||||
| Total Stockholders’ Equity | 46,140,339 | 25,535,660 | ||||||
| Total Liabilities and Stockholders’ Equity | $ | 84,368,878 | $ | 47,734,895 | ||||
5
CITIUS ONCOLOGY, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023
| 2024 | 2023 | |||||||
| Revenues | $ | — | $ | — | ||||
| Operating Expenses: | ||||||||
| Research and development | 4,925,001 | 4,240,451 | ||||||
| General and administrative | 8,148,929 | 5,915,290 | ||||||
| Stock-based compensation – general and administrative | 7,498,817 | 1,965,500 | ||||||
| Total Operating Expenses | 20,572,747 | 12,121,241 | ||||||
| Loss before Income Taxes | (20,572,747 | ) | (12,121,241 | ) | ||||
| Income tax expense | 576,000 | 576,000 | ||||||
| Net Loss | $ | (21,148,747 | ) | $ | (12,697,241 | ) | ||
| Net Loss Per Share – Basic and Diluted | $ | (0.31 | ) | $ | (0.19 | ) | ||
| Weighted Average Common Shares Outstanding – Basic and Diluted | 68,053,607 | 67,500,000 | ||||||
6
CITIUS ONCOLOGY, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023
| 2024 | 2023 | |||||||
| Cash Flows From Operating Activities: | ||||||||
| Net loss | $ | (21,148,747 | ) | $ | (12,697,241 | ) | ||
| Adjustments to reconcile net loss to net cash provided by operating activities: | ||||||||
| Stock-based compensation expense | 7,498,817 | 1,965,500 | ||||||
| Deferred income tax expense | 576,000 | 576,000 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Inventory | (2,133,871 | ) | - | |||||
| Prepaid expenses | (1,100,000 | ) | (5,044,713 | ) | ||||
| Accounts payable | 2,422,577 | 1,196,734 | ||||||
| Accrued expenses | (259,071 | ) | (801,754 | ) | ||||
| Due to related party | 14,270,648 | 14,805,474 | ||||||
| Net Cash Provided By Operating Activities | 126,353 | - | ||||||
| Cash Flows From Investing Activities: | ||||||||
| License payment | (5,000,000 | ) | - | |||||
| Net Cash Used In Investing Activities | (5,000,000 | ) | - | |||||
| Cash Flows From Financing Activities: | ||||||||
| Cash contributed by parent | 3,827,944 | - | ||||||
| Merger, net | (2,754,296 | ) | - | |||||
| Proceeds from issuance of note payable to related party | 3,800,111 | - | ||||||
| Net Cash Provided By Financing Activities | 4,873,759 | - | ||||||
| Net Change in Cash and Cash Equivalents | 112 | - | ||||||
| Cash and Cash Equivalents – Beginning of Year | - | - | ||||||
| Cash and Cash Equivalents – End of Year | $ | 112 | $ | - | ||||
| Supplemental Disclosures of Cash Flow Information and Non-cash Activities: | ||||||||
| IPR&D Milestones included in License Payable | $ | 28,400,000 | $ | - | ||||
| Capital Contribution of due to related party by parent | $ | 33,180,961 | $ | - | ||||
| Prepaid Manufacturing transferred to Inventory | $ | 6,134,895 | $ | - | ||||
7